Prescription-Only, Yet Everywhere: Advertising, Tele-Prescription and Enforcement Gaps in India's Post-Patent GLP-1 Market

Novo Nordisk's Indian patent on semaglutide expired in India on 20th March 2026, leading dozens of generic brands to enter the market and create cheaper generic medicines from local drug stores. Resulting in a huge price drop, with sales growing up to 235 percent year on year, and a prescription-only injectable began to resemble a mass-market lifestyle product, although only 0.1 per cent of obese Indians are reportedly on treatment. On the other hand, promotional pressure seems to be increasing as the gap between supply and uptake has grown. This article questions whether the Indian drug law is capable of regulating the creation of demand as effectively as the supply of the same. It interrogates the Drugs and Cosmetics Act, 1954, whose schedule lists obesity. The Central Drugs Standard Control Organisation (CDSCO) issued an advisory on 10th March 2026, the Supreme Court's 2024 ruling on endorsers' liability, along with the unfinished regulation on e- pharmacy and tele-prescription. Applying doctrinal analysis, official statements, market data, and a comparison with the United Kingdom's 2026 enforcement against social-media promotion of weight-loss injections, it provides the structural data for those who are answering at each link of the regulatory chain and recognises the three different gaps in it, which are: a manufacturer-facing advisory that does not visibly reach the influencers, various platforms, and clinics; the marketing approval, which is very difficult to verify in the prescribers' condition, following to an evidence gap, as the consequences of inspection, adverse events, and prescribing patterns are unpublished. It argues that the prohibition on advertising is constitutionally defensible but under-enforced, and that restrictions will push price-sensitive patients into grey markets. This suggests intermediary and endorser liability, GLP-1-centred tele-prescribing norms, verifiable electronic prescriptions, enforcement for citizens and pharmacovigil...